Free Paper Session   New Therapies for ARMD 1 Thursday 17 May 14:30 - 16:00 Salle Camille Blanc Presentations are 6 minutes in duration, followed by 2 minutes discussion I. Chowers, Y. Cohen, I. Hemo, E. Banin, E. Averbukh, M. Lederman, ISRAEL Evaluation of phenotype: Genotype correlation in neovascular age related macular degeneration R.R. Buggage, For The Macugen Primate Study Group, USA Electroretinographic parameters in monkey eyes are altered following intravitreal injections of bevacizumab but are unchanged by pegaptanib M. Falcão, R. Soares, Â. Carneiro, I. Azevedo, F. Falcão-Reis, PORTUGAL Effects of bevacizumab on HUVECs proliferation and apoptosis G.S. Dua, P.J. Ramana, R. Pearson, N. Karia, UK Intravitreal bevacizumab (Avastin) for the management of Retinal Pigment Epithelial Detachment (PED) with subretinal fluid in age related macular degeneration U. Introini, For The PERSPECTIVES Study Group, ITALY The PERSPECTIVES study J. Mones, SPAIN Quantification of visual acuity improvements over 2 years in the MARINA and ANCHOR studies of intravitreal ranibizumab A. Loewenstein, ISRAEL Patient-reported visual function outcomes over 2 years in the ANCHOR study comparing ranibizumab with verteporfin PDT P. Lanzetta, The MONT BLANC Study Group, ITALY MONT BLANC: Verteporfin PDT in combination with Ranibizumab for the treatment of subfoveal CNV due to AMD (SUMMIT trial programme) D. Calladine, V. Menezo, S.L. Watson, UK Retinal pigment epithelial tears following intravitreal ranibizumab (Lucentis®) for the treatment of exudative age-related macula degeneration G. Ravalico, E. Balestrazzi, A. Fantin, R. Fasciani, P. Iorio, ITALY First results of functional rehabilitation in patients with macular degeneration treated by phacoexeresis and IOL-VIP (Intra Ocular Lens - Visually Impaired People) system implantation